Alector, Inc. (ALEC)
Largest Insider Buys in Sector
ALEC Stock Price History Chart
ALEC Stock Performance
About Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Insider Activity of Alector, Inc.
Over the last 12 months, insiders at Alector, Inc. have bought $0 and sold $1.4M worth of Alector, Inc. stock.
On average, over the past 5 years, insiders at Alector, Inc. have bought $1M and sold $56.03M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,000 shares for transaction amount of $1M was made by Wehner David M. (director) on 2020‑02‑03.
List of Insider Buy and Sell Transactions, Alector, Inc.
| 2024-12-02 | Sale | Chief Executive Officer | 52,172 0.0534% | $2.52 | $131,442 | -12.55% | ||
| 2024-12-02 | Sale | President and Head of R&D | 26,500 0.0271% | $2.52 | $66,764 | -12.55% | ||
| 2024-12-02 | Sale | Chief Medical Officer | 14,892 0.0152% | $2.52 | $37,519 | -12.55% | ||
| 2024-12-02 | Sale | Chief Financial Officer | 16,489 0.0169% | $2.52 | $41,542 | -12.55% | ||
| 2024-09-03 | Sale | Chief Executive Officer | 26,499 0.0282% | $4.88 | $129,387 | +4.03% | ||
| 2024-09-03 | Sale | President and Head of R&D | 13,926 0.0148% | $4.88 | $67,981 | +4.03% | ||
| 2024-09-03 | Sale | Chief Medical Officer | 8,478 0.009% | $4.88 | $41,385 | +4.03% | ||
| 2024-09-03 | Sale | Chief Financial Officer | 7,297 0.0078% | $4.88 | $35,620 | +4.03% | ||
| 2024-08-22 | Sale | director | 44,250 0.0463% | $5.16 | $228,388 | -2.56% | ||
| 2024-08-12 | Sale | director | 5,000 0.0051% | $5.06 | $25,309 | -1.76% | ||
| 2024-08-12 | Sale | director | 10,500 0.0108% | $5.06 | $53,179 | -1.76% | ||
| 2024-06-03 | Sale | Chief Executive Officer | 25,135 0.0249% | $4.80 | $120,618 | -1.38% | ||
| 2024-06-03 | Sale | President and Head of R&D | 13,206 0.0131% | $4.80 | $63,373 | -1.38% | ||
| 2024-06-03 | Sale | Chief Medical Officer | 8,040 0.008% | $4.80 | $38,582 | -1.38% | ||
| 2024-06-03 | Sale | Chief Financial Officer | 6,920 0.0068% | $4.80 | $33,208 | -1.38% | ||
| 2024-03-04 | Sale | Chief Executive Officer | 18,837 0.0195% | $6.92 | $130,386 | -24.93% | ||
| 2024-03-04 | Sale | President and Head of R&D | 10,169 0.0105% | $6.92 | $70,387 | -24.93% | ||
| 2024-03-04 | Sale | Chief Medical Officer | 6,001 0.0062% | $6.92 | $41,554 | -24.93% | ||
| 2024-03-04 | Sale | Chief Financial Officer | 5,716 0.0059% | $6.92 | $39,562 | -24.93% | ||
| 2023-12-04 | Sale | Chief Executive Officer | 23,831 0.028% | $5.56 | $132,500 | -0.71% |
Insider Historical Profitability
| Rosenthal Arnon | Chief Executive Officer | 2507074 2.56% | $2.32 | 0 | 19 | |
| Kenkare-Mitra Sara | President and Head of R&D | 565215 0.5771% | $2.32 | 0 | 8 | |
| Romano Gary | Chief Medical Officer | 349283 0.3567% | $2.32 | 0 | 10 | |
| GRASSO MARC | Chief Financial Officer | 330651 0.3376% | $2.32 | 0 | 8 | |
| Yaffe Kristine | director | 67709 0.0691% | $2.32 | 0 | 1 | |
| Hammond Paula | director | 60209 0.0615% | $2.32 | 0 | 1 | |
| SCHELLER RICHARD H | director | 35000 0.0357% | $2.32 | 0 | 4 | |
| MCGUIRE TERRANCE | 10853817 11.0829% | $2.32 | 0 | 2 | ||
| Polaris Venture Management Co. VI, L.L.C. | 10 percent owner | 10853817 11.0829% | $2.32 | 0 | 2 | |
| GORDON CARL L | 10434976 10.6553% | $2.32 | 1 | 0 | +10.01% | |
| ORBIMED ADVISORS LLC | 10 percent owner | 1906718 1.947% | $2.32 | 1 | 17 | +10.01% |
| Oney Sabah | Chief Business Officer | 573918 0.586% | $2.32 | 0 | 11 | |
| King Robert | Chief Development Officer | 529295 0.5405% | $2.32 | 0 | 11 | |
| Paul Robert | Chief Medical Officer | 234319 0.2393% | $2.32 | 0 | 37 | |
| SULIMAN SHEHNAAZ | President and COO | 102598 0.1048% | $2.32 | 0 | 4 | |
| Yu Calvin | Vice President, Finance | 76686 0.0783% | $2.32 | 0 | 8 | |
| Wehner David M. | director | 44621 0.0456% | $2.32 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Fidelity Investments | $86.46M | 14.9 | 14.36M | +13.8% | +$10.49M | 0.01 | |
| BlackRock | $51.07M | 8.8 | 8.48M | +5.14% | +$2.5M | <0.01 | |
| The Vanguard Group | $29.57M | 5.1 | 4.91M | +11.99% | +$3.17M | <0.01 | |
| Ecor1 Capital Llc | $24.42M | 4.21 | 4.06M | 0% | +$0 | 0.17 | |
| State Street | $23.57M | 4.06 | 3.92M | +25.59% | +$4.8M | <0.01 | |
| Deep Track Capital Lp | $22.69M | 3.91 | 3.77M | New | +$22.69M | 0.1 | |
| Morgan Stanley | $19.9M | 3.43 | 3.3M | -28.93% | -$8.1M | <0.01 | |
| Deutsche Bank | $15.91M | 2.74 | 2.64M | +28.16% | +$3.5M | 0.01 | |
| Braidwell Lp | $14.33M | 2.47 | 2.38M | -28.39% | -$5.68M | 0.81 | |
| JPMorgan Chase | $10.33M | 1.78 | 1.72M | -7.95% | -$892,368.66 | <0.01 | |
| Geode Capital Management | $9.49M | 1.64 | 1.58M | +14.04% | +$1.17M | <0.01 | |
| Euclidean Capital Llc | $7.87M | 1.36 | 1.31M | 0% | +$0 | 1.01 | |
| Verition Fund Management Llc | $7.54M | 1.3 | 1.25M | +755.63% | +$6.66M | 0.07 | |
| Deerfield Management | $6.46M | 1.11 | 1.07M | +0.47% | +$30,310.70 | 0.02 | |
| Franklin Templeton Investments | $5.78M | 1 | 959,524 | 0% | +$0 | <0.01 | |
| Jacobs Levy Equity Management | $5.56M | 0.96 | 922,799 | +16.18% | +$773,660.30 | 0.02 | |
| DAFNA Capital Management, LLC | $5.5M | 0.95 | 912,928 | +49.68% | +$1.82M | 0.13 | |
| T. Rowe Price | $5.36M | 0.92 | 890,494 | -25.89% | -$1.87M | <0.01 | |
| Dimensional Fund Advisors | $5.09M | 0.88 | 845,964 | +10.67% | +$491,051.37 | <0.01 | |
| AllianceBernstein | $4.37M | 0.75 | 725,686 | +47.41% | +$1.41M | <0.01 | |
| Point72 Asset Management | $4.19M | 0.72 | 695,300 | +400.22% | +$3.35M | 0.01 | |
| Renaissance Technologies | $4.07M | 0.7 | 675,483 | +18.09% | +$623,007.54 | 0.01 | |
| Charles Schwab | $4.06M | 0.7 | 674,790 | +35.09% | +$1.06M | <0.01 | |
| Northern Trust | $4.03M | 0.7 | 670,223 | +9.06% | +$335,115.30 | <0.01 | |
| Sphera Fund | $3.37M | 0.58 | 560,000 | New | +$3.37M | 0.02 | |
| Two Sigma Advisers LP | $3.25M | 0.56 | 539,500 | +37.24% | +$881,328.00 | 0.01 | |
| Eversept Partners LP | $3.23M | 0.56 | 536,171 | New | +$3.23M | 0.25 | |
| Acadian Asset Management | $2.67M | 0.46 | 444,647 | +211.57% | +$1.82M | 0.01 | |
| Two Sigma | $2.2M | 0.38 | 364,629 | +89.37% | +$1.04M | <0.01 | |
| Bank of America | $2.13M | 0.37 | 353,651 | -19.68% | -$521,717.28 | <0.0001 | |
| Nuveen | $2.05M | 0.35 | 339,884 | -21.45% | -$558,698.23 | <0.01 | |
| New Leaf Venture Partners | $2.04M | 0.35 | 339,569 | 0% | +$0 | 1.95 | |
| D. E. Shaw & Co. | $1.98M | 0.34 | 329,625 | +79% | +$875,777.34 | <0.01 | |
| Baillie Gifford Co | $1.94M | 0.34 | 322,829 | -6.68% | -$139,031.93 | <0.01 | |
| Goldman Sachs | $1.92M | 0.33 | 319,265 | +11.67% | +$200,899.51 | <0.0001 | |
| Rafferty Asset Management Llc | $1.66M | 0.29 | 275,630 | +44.38% | +$510,008.50 | 0.01 | |
| Alyeska Investment Group L P | $1.54M | 0.27 | 256,182 | New | +$1.54M | 0.01 | |
| Walleye Capital | $1.52M | 0.26 | 252,808 | -3.56% | -$56,094.35 | <0.01 | |
| Citigroup | $1.45M | 0.25 | 240,976 | +191.94% | +$953,760.30 | <0.01 | |
| Jupiter Fund Management | $1.4M | 0.24 | 232,219 | 0% | +$0 | <0.01 | |
| BNY Mellon | $1.39M | 0.24 | 230,313 | +10.17% | +$127,991.20 | <0.0001 | |
| UBS | $1.38M | 0.24 | 229,486 | +28.43% | +$305,779.94 | <0.0001 | |
| Panagora | $1.32M | 0.23 | 219,704 | -7.16% | -$101,984.81 | 0.01 | |
| AQR Capital | $1.15M | 0.2 | 190,210 | +189.66% | +$749,748.73 | <0.01 | |
| Woodline Partners LP | $1.14M | 0.2 | 190,000 | New | +$1.14M | 0.01 | |
| Nordea Investment Management Ab | $1.16M | 0.2 | 188,767 | -0.8% | -$9,351.22 | <0.01 | |
| Medici Capital Llc | $1.12M | 0.19 | 185,929 | -3.54% | -$41,044.38 | 1.28 | |
| Marshall Wace | $1.07M | 0.18 | 177,278 | New | +$1.07M | <0.01 | |
| Alphabet | $1.06M | 0.18 | 175,866 | 0% | +$0 | 0.01 | |
| Stifel | $883,068.00 | 0.15 | 146,688 | +0.64% | +$5,592.62 | <0.01 |